Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Noile-Immune Biotech
company
About
Noile-Immune Biotech is a national cancer research center specializing in the development of cancer immunotherapies.
- 11 - 50
Details
- Last Funding Type
- Corporate Round
- Last Funding Money Raised
- ¥1B
- Industries
- Biotechnology
- Founded date
- Apr 1, 2015
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University.They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
¥3.44B
Noile-Immune Biotech has raised a total of
¥3.44B
in funding over 2 rounds. Their latest funding was raised on
Mar 22, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 22, 2021 | Series C | ¥2.38B | 2 |
BiGEN
|
— | Detail |
| May 31, 2018 | Series Unknown | ¥60M | 2 | — | — | Detail |
| Sep 4, 2017 | Corporate Round | ¥1B | 1 |
Takeda
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
4
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
BiGEN
|
Yes | Series C |
|
Takeda
|
Yes | Corporate Round |
Healthcare Innovation
|
— | Series C |
SAIKYO
|
— | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
